|
1
|
Nie X, Lin M, Xu S, Zhang L, Lin X, Huang W. Strategically reducing carbapenem-resistant Acinetobacter baumannii through PDCA cycle-driven antibiotic management. Indian J Med Microbiol 2024; 48:100527. [PMID: 38185209 DOI: 10.1016/j.ijmmb.2024.100527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 12/13/2023] [Accepted: 01/02/2024] [Indexed: 01/09/2024]
Abstract
PURPOSE With the escalating global challenge of antibiotic resistance, particularly the resistance rate of Acinetobacter baumannii, the need to rationalize carbapenem antibiotic use in clinical settings has become paramount. Our study tapped into a fishbone diagram to uncover the irrationalities in applying these antibiotics and highlight potential influencing factors. METHODS Based on these analyses, we initiated targeted intervention strategies. A PDCA cycle-based scientific management approach was implemented through the combined efforts of our antimicrobial stewardship team and relevant departments. RESULTS Our study showed a significant post-intervention increase in the rational use of carbapenem antibiotics (P < 0.01) and a concurrent decrease in the detection of carbapenem-resistant Acinetobacter baumannii. CONCLUSION Our findings underscore that carbapenem usage can be effectively minimized with the continuous refinements offered by the PDCA cycle, leading to a reduction in multidrug-resistant bacteria, thus fostering rational drug use in healthcare.
Collapse
Affiliation(s)
- Xuekun Nie
- Department of Clinical Pharmacy, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, 352100, China; Collaborative Innovation Center of Active Ingredient Research of She Medicine (2020Z03), Innovation Center of Clinical Pharmacy Service (2023T06), Ningde Normal University, Ningde, Fujian, 352100, China.
| | - Minhua Lin
- Department of Clinical Pharmacy, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, 352100, China; Collaborative Innovation Center of Active Ingredient Research of She Medicine (2020Z03), Innovation Center of Clinical Pharmacy Service (2023T06), Ningde Normal University, Ningde, Fujian, 352100, China.
| | - Shuanglin Xu
- Department of Clinical Pharmacy, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, 352100, China; Collaborative Innovation Center of Active Ingredient Research of She Medicine (2020Z03), Innovation Center of Clinical Pharmacy Service (2023T06), Ningde Normal University, Ningde, Fujian, 352100, China.
| | - Lingling Zhang
- Department of Clinical Pharmacy, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, 352100, China; Collaborative Innovation Center of Active Ingredient Research of She Medicine (2020Z03), Innovation Center of Clinical Pharmacy Service (2023T06), Ningde Normal University, Ningde, Fujian, 352100, China.
| | - Xiaohui Lin
- Department of Clinical Pharmacy, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, 352100, China; Collaborative Innovation Center of Active Ingredient Research of She Medicine (2020Z03), Innovation Center of Clinical Pharmacy Service (2023T06), Ningde Normal University, Ningde, Fujian, 352100, China.
| | - Weiying Huang
- Department of Clinical Pharmacy, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, 352100, China; Collaborative Innovation Center of Active Ingredient Research of She Medicine (2020Z03), Innovation Center of Clinical Pharmacy Service (2023T06), Ningde Normal University, Ningde, Fujian, 352100, China.
| |
Collapse
|